

IN THE CLAIMS

Claim 27 has been deleted in its entirety and replaced with:

--A substantially pure GD2 ligand, wherein said GD2 ligand comprises the peptide of GGITNYNSALM (SEQ ID NO: 3).--

Claim 28 has been deleted in its entirety and replaced with:

--A substantially pure synthetic or recombinant GD2 ligand, wherein said GD2 ligand comprises the peptide of GGITNYNSALM (SEQ ID NO: 3).--

In claims 50-51, the term "recombinant" has been deleted.

*PPAP 4/4/08*  
<sup>53</sup>  
In claims 52-~~52~~, line 1, the term "ablating" has been deleted, and the term --treating— inserted.

Claims 29-30, 33-45, and 54-60 have been cancelled without prejudice.

*Reasons for Allowance*

The following is an examiner's statement of reasons for allowance: A substantially pure GD2 ligand, or synthetic/recombinant thereof, comprising SEQ ID NO: 3, was not found to be reasonably taught or suggested by the prior art of record, nor was the product as a T-cell receptor/expressed within a cytotoxic T cell line, or a method of treating a cell line using the same (as shown capable of on page 31, last para, specification).

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue